Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Urigen Pharmaceuticals, Inc. | ex991.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 5, 2012
Urigen Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
0-22987
|
94-3156660
|
||
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification
No.)
|
|
501 Silverside Road PMB#95, Wilmington, DE
|
19809
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (925) 280-2861
1700 North Broadway, Suite 330, Walnut Creek, CA 94596
(Former name or former address, if changed since last report)
Copies to:
Marc Ross, Esq.
Thomas Rose, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10018
Phone: (212) 930-9700
Fax: (212) 930-9725
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
/_/ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
/_/ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
/_/ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
/_/ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01. Other Events
On June 5, 2012, Urigen Pharmaceuticals, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
|
Exhibit Number
|
Description
|
|
| 99.1 | Press Release issued by the Company on June 5, 2012. |
2
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the Undersigned, thereunto duly authorized.
|
Urigen Pharmaceuticals, Inc.
|
|||
|
Date: June 7, 2012
|
By:
|
/s/ Dan Vickery | |
| Dan Vickery | |||
| Chairman | |||
3